Patent intelligence · US
US 12404328
Multi-specific binding proteins and methods of use thereof
Multi-specific binding proteins and methods of use thereof
Patent details — US 12404328
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 2, 2025
- Expiration
- Aug 28, 2045
- Applicant
- Cullinan Management, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 12404328 (Multi-specific binding proteins and methods of use thereof) is held by Cullinan Management, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cullinan Management, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
More from Cullinan Management, Inc.
Related pharmaceutical patents in our USPTO index.
Related coverage
Medicare price rule could hit Keytruda and Opdivo subcutaneous launches
CMS is proposing a Medicare drug price rule that could shape the outlook for subcutaneous Keytruda and Opdivo. The products are expected to be eligible for selection in the 2027 negotiation round for IPAY 2029.
FDA approves belzutifan plus pembrolizumab for adjuvant RCC
The FDA approved belzutifan plus pembrolizumab as adjuvant therapy for clear cell renal cell carcinoma at high risk of recurrence after nephrectomy. The catalyst is based on phase 3 LITESPARK-022 data and adds another regulatory milestone for belzutifan.
FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC
The FDA granted priority review to supplemental applications for belzutifan plus pembrolizumab in adjuvant renal cell carcinoma. The move extends Merck’s renal cancer catalyst path after evidence showed improved disease-free survival versus pembrolizumab alone.
FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
The FDA approved pembrolizumab (Keytruda) for adjuvant treatment of stage IB, II, and IIIA non-small cell lung cancer after resection and platinum chemotherapy. For Merck and investors, the key readout is how this label expansion may shape lung cancer franchise momentum and future catalyst tracking.
Frequently asked questions
What is US patent 12404328?
US 12404328 (Multi-specific binding proteins and methods of use thereof) is held by Cullinan Management, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12404328?
Cullinan Management, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12404328 expire?
Our index shows an expiration date of Aug 28, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.